Literature DB >> 12351788

Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").

George A Ricaurte1, Jie Yuan, George Hatzidimitriou, Branden J Cord, Una D McCann.   

Abstract

The prevailing view is that the popular recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") is a selective serotonin neurotoxin in animals and possibly in humans. Nonhuman primates exposed to several sequential doses of MDMA, a regimen modeled after one used by humans, developed severe brain dopaminergic neurotoxicity, in addition to less pronounced serotonergic neurotoxicity. MDMA neurotoxicity was associated with increased vulnerability to motor dysfunction secondary to dopamine depletion. These results have implications for mechanisms of MDMA neurotoxicity and suggest that recreational MDMA users may unwittingly be putting themselves at risk, either as young adults or later in life, for developing neuropsychiatric disorders related to brain dopamine and/or serotonin deficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351788     DOI: 10.1126/science.1074501

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  35 in total

1.  Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.

Authors:  A C Parrott; T Buchanan; T M Heffernan; A Scholey; J Ling; J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

2.  When to retract?

Authors:  Richard Smith
Journal:  BMJ       Date:  2003-10-18

3.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

4.  Editorial note: MDMA-induced dopamine neurotoxicity.

Authors:  David M Warburton
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

5.  The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).

Authors:  A C Parrott; J Rodgers; T Buchanan; A B Scholey; T Heffernan; J Ling
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

6.  Science forced to retract article on "ecstasy".

Authors:  Stephen Pincock
Journal:  BMJ       Date:  2003-09-13

7.  Realities at the leading edge of research.

Authors:  William Alexander; Joshua Berlin; Philip Cyr; Andrew Schofield; Leslie Platt
Journal:  EMBO Rep       Date:  2004-04       Impact factor: 8.807

8.  MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press.

Authors:  A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-02-20       Impact factor: 4.530

Review 9.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 10.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.